Experience

Sonata Therapeutics
• United States
• Biotechnology Research
• 1 - 100 Employee
• Senior Scientist II

  • Sep 2022 - Present

Inzen Therapeutics
• United States
• Biotechnology Research
• 1 - 100 Employee
• Senior Scientist

  • Jul 2021 - Sep 2022


Oklahoma State University

• United States
• Higher Education
• 700 & Above Employee

• Research Associate PhD

  • Mar 2019 - Jul 2021

  • Evaluated the role of iron mediated lung epithelial cells injury in lung fibrosis using different chemically and genetically induced lung fibrosis models• Assessed the role of lung epithelial cells derived exosomes in lung fibrosis • In vivo models:Bleomycin and Asbestos induced lung fibrosis mouse modelSFTPC Cre// Gpx4 knockout mouse model

• Research Associate PhD

  • Mar 2017 - Mar 2019

  • Evaluated the role of nanoparticles containing long non-coding RNA and high intensity focused ultrasound (HIFU) on tumor immunomodulation. • Assessed the role of long non-coding RNA in tumorassociated macrophage polarization and fibroblast activation

• Research Associate PhD

  • Mar 2016 - Mar 2017

  • Evaluated the role of long non-coding RNA (LncRNAs) and miRNA on macrophage polarization• Assessed the role of long non-coding RNA induced M1 macrophage polarization in lung fibrosis

• Research Associate PhD

  • Oct 2010 - Mar 2016

  • Evaluated the role of molecular mechanisms involved in the development of liver and kidney cysts in Xylosyltransferase 2 knock-out mice• Performed biliary epithelial tract isolation from three different genetic mouse models for polycystic kidney and liver disease: Xylosyltransferase 2 deficient mice (Xylt2-/-) 129 background; Pkhd1del3-4 C57Bl/6J background; Xylt2-/-:Ccr2-/- 129 backgound)• Evaluated the functional interactions between extracellular matrix proteoglycans and inflammatory environment involved in liver and kidney cyst progression